NGO Microgen, begins production of a novel multicomponent probiotic within the course of import substitution

10.02.2015
In February 2015, experts of the Perm NGO Biomed, a branch of NGO Microgen, were granted a marketing authorization for a new dosage form, lyophilizate, of an effective probiotic Bifilac-Beals that includes 3 strains of bifidobacteria and lactobacilli, proven in therapeutic practice. Specially selected composition of the drug combines compatible strains which together ensure high quality characteristics of the product intended for correction of human GIT microflora in complex treatment of infectious and non-infectious diseases.

The drug has successfully passed clinical trials, and production of two presentations has been planned for the near future: hard gelatin capsules and lyophilizate (dry bacterial biomass) in a vial.

The organization of Bifilac-Beals manufacturing process meets the import substitution strategy, ensuring presence of a competitive probiotic complex on the domestic pharmaceutical market that has a number of consumer benefits in comparison with the foreign analogs. The new probiotic has high antagonistic activity against pathogenic and conditionally pathogenic bacteria.

As a result of the practical use of the drug, the manufactured range of dosage forms will be adjusted according to the wishes of consumers and the medical community.

Keep in mind that NGO Biomed in Perm is the oldest Russian enterprise that develops and manufactures a broad range of vaccines and immubiological drug products. The branch occupies a leading position in processing of human blood plasma in Russia. Currently, according to the basic measures for implementation of the "Strategy of Development of the Pharmaceutical Industry in the Russian Federation till 2020", NGO Biomed in Perm has been intensely working on reconstruction and re-equipment of the main production areas; special attention is paid to organization of finishing operations in accordance with GMP requirements.